Community/Retail

FDA approves a new dosing schedule for donanemab, enhancing safety and efficacy in treating early symptomatic Alzheimer disease.

Packed with CE sessions, interactive learning, expert insights, and a vibrant expo floor, McKesson ideaShare 2025 aims to equip independent pharmacists with the tools and strategies to elevate patient care and drive pharmacy innovation.

In a community of older adults, initiating a pneumococcal vaccination support program reduced annual pneumonia-related mortality by 25%, demonstrating broad public and individual health benefits.

The conference offers immersive, peer-driven education tracks designed to help independent pharmacies innovate, adapt, and thrive in a changing health care landscape.

Understanding RSV’s impact on respiratory and cardiovascular health underscores the importance of holistic management, prevention through vaccination, and continued innovation in treatment strategies.

Real-world studies reveal GLP-1 medications like semaglutide and tirzepatide yield less weight loss than clinical trials, highlighting treatment discontinuation challenges.

The FDA is warning of rare severe itching after stopping long-term use of popular allergy medications cetirizine and levocetirizine, urging patient education.

AI is revolutionizing pharmacovigilance by enhancing data analysis, improving patient safety, and enabling proactive risk management in drug monitoring.

The lawsuit alleges that Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. violated the law when issuing new guidance for COVID-19 vaccination.

Experts discussed the promising future of pericarditis treatment.

Funding cuts to public health agencies threaten to worsen chronic diseases and ignite infectious disease outbreaks, straining health care systems nationwide.

Y-90 resin microspheres offer a new option for patients with liver cancer for the treatment of unresectable hepatocellular carcinoma.

Andrew E. Esch, MD, MBA, discusses the need for systemic reforms to support pharmacist-led medication optimization in palliative and community-based care.

Prescription digital therapeutics (PDTs) offer scalable, accessible alternatives to traditional treatments—supporting patients, providers, and payers while addressing gaps in mental health care.

Stroke, myocardial infarction, and all-cause death were included in the composite of adverse cardiovascular events.

Six months following discharge from the hospital, adults who battled community-acquired pneumonia were at heightened risk of losing the ability to perform activities and experiencing poor quality of life.

Real-world data show that patients switching from Humira to biosimilars Hadlima and Hyrimoz achieve similar outcomes without hospitalization.

Recent research reveals that RSV and shingles vaccines significantly lower dementia risk, highlighting the potential benefits of AS01 adjuvants in vaccination.

Expert explores the expanding role of FDA-approved Prescription Digital Therapeutics (PDTs).

An expert discusses the challenges of diagnosing and treating RSV in older adults and highlights the critical role of prevention.

Research reveals a link between estrogen plus progestin hormone therapy and increased breast cancer risk in young women, urging personalized treatment approaches.

Vitamin C enhances skin health by promoting epidermal cell growth and regeneration, offering a potential solution for aging and thinning skin.

Lung transplant recipients were found to be at heightened risk of developing secondary lung infections, including bacterial and fungal infections, due to unique risk factors.

The injection is indicated for the treatment of sepsis and other serious infections, enhancing treatment efficiency and patient care.

A low-fat vegan diet reduces dietary acid load and promotes weight loss more effectively than a Mediterranean diet.

Simplifying complex information through illustrations has consistently helped patients feel that managing type 1 diabetes is achievable.

Pharmacists and clinicians collaborate to carefully manage rilonacept therapy.

Across 3 different manufacturing lots, V116 (21-valent pneumococcal conjugate vaccine) demonstrated consistent immunogenicity and efficacy against S pneumoniae, which causes pneumococcal diseases.